1. Indications and Usage
\nNTRK Fusion-Positive Solid Tumors: Treatment of adult and pediatric patients with solid tumors that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without known acquired resistance mutations, who have metastatic disease or where surgical resection is likely to result in severe morbidity, and who have no satisfactory alternative treatments or have progressed on prior treatment .
\nTumor Agnostic: Indications cover various tumor types (e.g., thyroid cancer, sarcoma, salivary gland cancer) provided the NTRK fusion status is confirmed .
\n2. Dosage and Administration
\nAdministration: Oral administration. Hard capsules must be swallowed whole with water. Do not open, chew, or crush the capsules as contents are bitter .
\nFood Requirement: Can be taken with or without food. Avoid grapefruit or grapefruit juice .
\nStandard Dose:
\nAdults: 100 mg twice daily .
\nPediatrics (BSA \u22651.0 m\u00b2): 100 mg twice daily .
\nPediatrics (BSA <1.0 m\u00b2): 100 mg\/m\u00b2 twice daily (maximum single dose 100 mg) .
\nMissed Dose: If a dose is missed and it is less than 6 hours before the next scheduled dose, skip the missed dose. Do not take a double dose .
\nDose Adjustment: Mandatory dose reduction (e.g., by 50%) for severe hepatotoxicity or neurotoxicity (Grade 3 or higher) .
\n3. Mechanism of Action
\nLarotrectinib is a potent, selective inhibitor of the tropomyosin receptor kinase (TRK) family (TRKA, TRKB, and TRKC).
\nIt is encoded by the NTRK1, NTRK2, and NTRK3 genes.
\nBy blocking these kinases, larotrectinib inhibits the phosphorylation of TRK, leading to inhibition of tumor cell proliferation and induction of apoptosis .
\n4. Safety and Warnings
\nHepatotoxicity: Elevations in ALT and AST are common. Monitor liver function tests before initiation and during treatment .
\nNeurotoxicity: Can cause CNS effects (e.g., dizziness, cognitive impairment, ataxia). Patients should avoid driving if these occur .
\nEmbryo-Fetal Toxicity: May cause fetal harm. Contraception is required for females and males during treatment and for at least 1 week after the final dose .
\nMuscle Damage: Monitor Creatine Kinase (CK) levels if muscle pain or weakness occurs .
\n5. Adverse Reactions
\nCommon adverse reactions (incidence \u226520%) include:
\nGeneral: Fatigue, pyrexia.
\nGastrointestinal: Nausea, diarrhea, vomiting, constipation, dysgeusia.
\nCNS: Dizziness, cognitive impairment.
\nLaboratory Abnormalities: Increased AST, increased ALT, anemia .
\n6. Drug Interactions
\nCYP3A Inhibitors: Avoid co-administration with strong CYP3A inhibitors (e.g., ketoconazole) as they increase Larotrectinib exposure. If unavoidable, reduce dose by 50% .
\nCYP3A Inducers: Avoid co-administration with strong CYP3A inducers (e.g., rifampin) as they reduce efficacy .
\n7. Pharmaceutical Information
\nChemical Name: Larotrectinib Sulfate .
\nMolecular Formula: C21H23ClN6O4 \u00b7 H2SO4 .
\nStorage: Store at 20\u00b0C to 25\u00b0C (68\u00b0F to 77\u00b0F); excursions permitted to 15\u00b0C to 30\u00b0C (59\u00b0F to 86\u00b0F) .<\/p>\n","protected":false},"excerpt":{"rendered":"
Brand Name: \u7ef4\u6cf0\u51ef\u00ae (Vitrakvi\u00ae)
\nGeneric Name: Larotrectinib Sulfate
\nStrength: 100 mg per hard capsule, 56 capsules per box
\nManufacturer: Bayer AG\uff08\u62dc\u8033\uff09\u59d4\u6258\u751f\u4ea7\u4f01\u4e1a
\nMarketing Authorization Holder: Bayer AG\uff1b\u56fd\u5185\u5883\u5185\u4ee3\u7406\u4eba\uff1a\u62dc\u8033\u533b\u836f\u4fdd\u5065\u6709\u9650\u516c\u53f8
\nApproval Date in China: April 13, 2022
\nRegistration Number: \u56fd\u836f\u51c6\u5b57HJ20220010
\nStorage: Store sealed at 20\u2103\u201325\u2103, temporary exposure between 15\u2103\u201330\u2103 is allowed; protect from light and moisture, keep out of reach of children<\/p>\n
Price&Cost:Contact Us now for the best price of Larotrectinib Sulfate\uff08Vitrakvi\uff09<\/p>\n","protected":false},"featured_media":2870,"comment_status":"open","ping_status":"closed","template":"","meta":[],"product_brand":[86],"product_cat":[26],"product_tag":[],"class_list":["post-2869","product","type-product","status-publish","has-post-thumbnail","product_brand-bayer","product_cat-capsules","first","instock","shipping-taxable","product-type-simple"],"yoast_head":"\n